Drug Trial Radar · NCT01077817
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
684,815
Actual
Start
Feb 26, 2010
Primary completion
Feb 16, 2012
Study completion Feb 16, 2012
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- Collaborators
- World Health Information Science Consultants, LLC
- First posted
- Mar 1, 2010
Design
- Study type
- Observational
- Who can join
- Female only, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.
Conditions
- Esophageal Cancer
- Squamous Cell Carcinoma
- Adenocarcinoma
Interventions
AlendronateDrug
EtidronateDrug
IbandronateDrug
RisedronateDrug
RaloxifeneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis)Time frame: Exposure to study drug at least 720 days before disease onset
- Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)Time frame: Up to approximately 7.3 years of follow-up
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.